FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
New colon cancer study results reported from University of Colorado
April 23rd, 2009
According to a study from the United States, "Despite the availability of several Food and Drug Administration-approved drugs, advanced inoperable colorectal cancer remains incurable. In this study, we focused on the development of combined molecular targeted therapies against colon cancer by testing the efficacy of the combination of the histone deacetylase inhibitor vorinostat with the proteasome inhibitor bortezomib to determine if this resulted in synergistic antitumor effects against colorectal cancer." "The effects of the histone deacetylase inhibitor vorinostat in combination with the proteasome inhibitor bortezomib on the growth of two colorectal cancer cell...
Source: FDA Law Weekly (2009-04-23)
|
